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Background: The natural history of inhibitors in patients with haemophilia A not undergoing immune tolerance
induction (ITI) is largely unknown. A recent randomized controlled trial suggests that the higher the FVIII dose used
for ITI, the faster the clearance and the lower the rate of bleeding, without any difference in the rate of tolerance.
We aimed at assessing the rate of spontaneous inhibitor clearance in a large cohort of patients not undergoing ITI.
Methods: A retrospective analysis of anti-FVIII inhibitors of long-term registry data in a single centre cohort of 524
haemophilia A patients considered for synovectomy was performed. Patients were tested for inhibitors before and
15 days after any and each surgical episode and thereafter did not undergo immune tolerance at any time.
Results: The cumulative incidence of inhibitors overall was 34% (180 out of 524) with the highest percentage of
39% (168 out of 434) in severe patients which represented 83% of the cohort. Among the 180 inhibitor patients: 63
had permanent inhibitors; 70 fulfilled current criteria for transient inhibitors but a third category of 47 additional
patients cleared the alloantibody spontaneously in >6 months. At logistic regression, both the inhibitor titre and
the gene mutation were shown to predict time to clearance.
Conclusions: Spontaneous clearance of inhibitors over variable time in the absence of ITI treatment was found in
up to 2/3 of the cases.
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Haemophilia A treatment, consisting of the administra-
tion of factor VIII (FVIII) concentrates, can be compli-
cated in a variable percentage of cases (0-50%) by the
occurrence of inhibitor antibodies, which render treat-
ment ineffective [1-4]. A proportion of these antibodies
thereafter disappear; antibodies cleared within 6 months
are known as 'transient' while those lasting longer are
called 'persistent' and are deemed to continue through-
out the patient’s life [5,6]. With the aim of eradicating
the inhibitor, these patients are treated with high dose* Correspondence: giuseppe.tagariello@ulssasolo.ven.it
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reproduction in any medium, provided the orFVIII, referred to as 'immune tolerance induction' (ITI).
ITI positively affects the life of haemophilia patients by
reducing the time to inhibitor eradication and the bleed-
ing rate while on treatment [7], but its widespread adop-
tion made and makes it very difficult to understand the
natural history of inhibitors.
Very little is actually known about the natural long term
history of inhibitors in absence of ITI, even though a sem-
inal observation of spontaneous resolution of inhibitors in
patients who continued to be exposed to standard doses
of FVIII was reported by Rizza and Matthews [8]. More
recent work has indicated the possibility that non-
tolerized inhibitors may present different patterns over
time including not only 'stable positivity' or 'stable negativ-
ity', but also a third category named 'unstable' [9]. A betterral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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undergoing ITI is essential to clarify the still unknown im-
munological mechanism underlying ITI [10] and to appro-
priately evaluate its efficacy [11,12], which is particularly
important in view of the huge costs of this treatment (in
the region of £2,000,000 per treatment in 2003) [13]. In
fact, the estimate of the proportion of spontaneously re-
solving inhibitors in the haemophilia population is critical,
jointly with evidence that ITI speeds up the process of
spontaneous tolerance more than it affects the rate of in-
hibitor clearance [7], to understand the role for ITI as
compared to alternative management strategies.
With the specific purpose of further clarifying the
natural history of inhibitors in terms of clearance rate
and time, a single centre retrospective study was
performed on a prospectively followed cohort of non-
tolerized, mostly genotyped patients with haemophilia
A and inhibitors.Methods
Study population
A cohort of patients from one centre (Castelfranco Veneto
Haemophilia Centre) where surgical synovectomy was
adopted, in the 70s and 80s, as the main treatment
method and where inhibitor patients had never undergone
ITI.
This was a database originated research. Data were
extracted anonymously from the database of clinical and
laboratory data of the Hemophilia Center in Castelfanco
Veneto. A generic consent to store information for re-
search purposes was obtained from the patients over
time, but, for the need of gathering a complete inception
cohort, no specific consent was sought for this specific
retrospective study protocol.
Haemophilia A was diagnosed and classified according
to factor VIII plasma levels [14]. Inhibitor titre was
assessed by the Bethesda assay based on measuring the
amount of FVIII inactivated by patient plasma mixed in
equal proportions with pooled normal plasma as a
source of FVIII [15]. For the purpose of this analysis in-
hibitors were considered 'low' if the titre was < 5 BU/ml
and 'high' if it was > 5 BU/ml and patients accordingly
defined as low and high responders respectively.
The cohort consisted of all consecutive patients admit-
ted to the centre from 1973–2010 who were tested for
inhibitors the first time and at least 5 more times during
a minimum 24-month follow up period and 3-month
minimum interval between each test. Patients were regu-
larly tested for inhibitors before and 2 weeks after surgi-
cal synovectomy.
Patients with less than 5 tests were excluded. Exposure
days before inclusion in the study cohort ranged from 0
to >200 while all the inhibitor negative patients reached200 exposure days during follow up. The entire cohort
was treated with factor concentrates approved and avail-
able at the time, i.e. cryoprecipitate at the beginning,
then plasma derived concentrates manufactured from
Italian plasma (by FarmaBiagini and subsequently
Kedrion, as Koate, Uman-Cry and Emoclot) and lately
recombinant concentrates (used in a minority of pa-
tients). Bypassing agents were used to treat bleedings in
patients with high inhibitor titre. When patients
reached a low inhibitor level (= < 5 BU), they were
treated with FVIII concentrates for spontaneous bleed-
ing or for surgery. In these cases, FVIII was dosed cal-
culating a neutralizing dose (BU × 40 × kg/bw) and
adding it to the dose needed for the targeted increment
in the patient plasma factor VIII level (frequently in the
range of 30–50 IU kg/bw). When treated, patients were
closely monitored for any anamnestic response by la-
boratory testing every other day for 1 or 2 weeks. Most
of the increases in titer occurred within an average of
6 days (range 3–10).
Time-dependent classification of inhibitors
Inhibitors were classified as follows: 'transient' if the in-
hibitor disappeared spontaneously within 6 months and
did not reappear when the patient was exposed to factor
VIII; 'slowly resolving' if the inhibitor disappeared spon-
taneously after 6 months and did not reappear when ex-
posed to factor VIII; 'persistent' if the inhibitor remained
positive or could not be detected in the absence of factor
VIII treatment but reappeared when factor VIII was re-
administered.Mutation analysis
From the Italian Registry of Haemophilia A Mutations
[16], it was possible to identify patient mutations, classi-
fied accordingly as, inversions (int1inv and int22inv),
null mutations (large deletions, nonsense and frameshift
ins/del) or not null mutations (all the others).Statistical analysis
To estimate and compare the probability of inhibitor reso-
lution, we have used a model of clinical outcome (class of
inhibitor) as predicted by immunological response (high
versus low) and gene mutation (inversion, null, not null)
using a multinomial logistic regression.Results
Patients
The total number of patients was initially 543. They
were all tested for inhibitors at least once but 19 pa-
tients, with less than 5 tests, were excluded from the
analysis (Figure 1).
N = 543
Patients with at least 1 inhibitor test
N = 524
Patients with moret han 5 inhibitor tests. 
Included
N = 19








N = 50 
Moderate negative patients
N = 266 
Severe negative patients
N = 28 
Mild negative patients





Mild positive patients 
Transient 64 (38%)
Slowly resolving 44 (26%)
Permanent 60 (36%)
Transient 5 (50%)
Slowly resolving 2 (20%)
Permanent 3 (30%)
Transient 1 (50%)
Slowly resolving 1 (50%)
Permanent 0
Figure 1 Flow chart of the cohort of patients seen at Castelfranco Veneto Haemophilia Centre, 1973–2010.
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In total, 7,779 test results were available with a median
of 15 tests per patient (Figure 2). The mean (+/− SD)
age at the onset of inhibitors was 17+/−8 yrs (range 3–
47). The mean (+/− SD) follow up was 24+/−12 yrs
(range 8–36).
The cumulative inhibitor incidence total was 34%
(180/524), 39% (168/434) in severe cases, 16% (10/60) in
moderate ones and 7% (2/30) in mild patients. The dis-
tribution of inhibitors in persistent, slowly resolving and
transient according to haemophilia severity and inhibitor
characteristics is reported in Figure 1 and Table 1. 29 in-
hibitor patients were found positive when first tested, of
these, 22 were high responders and 7 low.
Mutations
Mutations were identified in 335/524 patients (64%).
Transient, slowly resolving, persistent inhibitor distribu-
tion and titre is shown in Table 2. The presence of inver-
sions/null mutations was higher in the persistent and
high responding inhibitor groups. The median persist-
ence time of spontaneously clearing slowly resolving in-
hibitors is reported in Table 3.Logistic regression analysis
The characteristics of the models and analysis details
are reported in Table 4 and its legend. Since underlying
gene mutation data was known in only a proportion
(131/180) of inhibitor patients the probability of devel-
oping a transient, slowly resolving or permanent inhibi-
tor was estimated in two different ways. If available, the
probability associated with both the initial inhibitor titre
and the gene mutation was assessed, otherwise only the
inhibitor titre was used.
The relative risk ratio between a high and low re-
sponder in having a slowly resolving inhibitor is 3.63
(95% CI 1.39 – 9.47) and a permanent inhibitor 62 (95%
CI 21.12 – 182.00). In the full model - inhibitor titre,
gene mutation and their interactions, the effect of the
titre was not statistically significant when considered
alone, whereas, in patients with inversions compared to
those with non null mutations a statistically significant
and clinically relevant increase in the risk for permanent
inhibitors in patients with high titre inhibitors (21.7,
95% CI 1.80 – 263) was found. It was not possible to as-
sess the effect of large mutations in this study due to
their relatively low incidence.
Figure 2 The figure shows tests for inhibitors (upper curve) and surgical synovectomy performed at Castelfranco Veneto Haemophilia
Centre, 1973–2010. The majority of the tests were performed during the period 1973–1990 when most of the surgical synovectomy
programme was developed. The curve shows two peaks, the first during the 70s when the synovectomy programme was more intensive and the
second during the mid-80s when patients undergoing synovectomy were overlapped by patients regularly followed up for inhibitor. The last two
decades represent the follow up of the patients (right upper curve) and more recent years when surgical synovectomy was completely
abandoned and substituted by synoviorthesis (data not reported).
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This work reports the natural history of inhibitors in a
cohort of patients followed up for more than 35 years,
receiving FVIII replacement therapy but never ITI. In
64% of the patients the inhibitor was spontaneously
cleared over a period of up to 12 years. As to risk fac-
tors for inhibitors, the study confirms that null muta-
tions are strong predictors of inhibitor development,
and it adds that the combination of inhibitor titre andTable 1 Distribution of patients with and without inhibitor de
resolving and permanent, dependent on the severity of the d
Severe Moderate Mild
n = 434 n = 60 n = 30
Without inhibitor 266 50 28
With inhibitor 168 10 2
Transient 64 (38%) 5 (50%) 1 (50%)
Slowly resolving 44 (26%) 2 (20%) 1 (50%)
Permanent 60 (36%) 3 (30%) 0
The condition of HR at the onset confers the highest risk of persistent inhibitor (56
the onset is as LR (7 out of 101, 7%).
(*)The OR represents the risk of having a permanent or slow resolving inhibitor forgene mutation type is a possible predictors of spontan-
eous inhibitor remission. The role of these results in
understanding the mechanism and impact of ITI on
the natural history of inhibitors requires further study.
Strengths of the study
The patients were tested every time they underwent
surgical synovectomy or exposure to factor VIII for
bleeding at the optimal time of two weeks after FVIIIvelopment, high and low responders, transient, slowly
isease
Total High responders Low responders OR
n = 524 n = 79 n = 101 (*)
344
180
70 (39%) 8 (10%) 62 (61%) -
47 (26%) 15 (19%) 32 (32%) 3.6
63 (35%) 56 (71%) 7 (7%) 62
out of 79, 71%) while only a minority of the patients become persistent when
those being HR as compared to those being LR.
Table 2 Distribution of patients with and without inhibitor, high and low responders, transient, slowly resolving and
permanent dependent on the mutation type
N° of patients NULL mutations inversions (Int1/22) NULL mutations other NOT null mutations Unknown mutation Total
N = 156 N = 79 N = 91 N = 198 N = 524
Without inhibitor 87 40 68 149 344
With inhibitor 69 39 23 49 180
Transient 17 (25%) 14 (36%) 10 (44%) 29 (59%) 70 (39%)
Slowly resolving 20 (29%) 6 (15%) 7 (30%) 14 (29%) 47 (26%)
Permanent 32 (46%) 19 (49%) 6 (26%) 6 (12%) 63 (35%)
High Responders 38 (55%) 21 (54%) 7 (30%) 13 (27%) 79 (44%)
Low Responders 31 (45%) 18 (46%) 16 (70%) 36 (73%) 101 (56%)
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inhibitors testing was necessary to avoid the risk of un-
controlled bleeding during synovectomy. The results of
this close observation has made feasible a study, based
on a cohort subjected to stringent follow up and well-
documented inhibitor incidence from as far back as the
70s and 80s, when inhibitor testing was not routinely
performed in all Haemophilia Centres.
Due to the early implementation of this strategy, it
has been possible to detect all the patients with inhibi-
tors, including low titre as well as transient ones and
to identify subgroups of patients on the basis of differ-
ent time-dependent inhibitor clearance. On the oppos-
ite, inhibitor surveillance programs started worldwide
as recombinant products became available and were
not as suitable to assess the natural history of inhibi-
tors because in the meanwhile ITI has become wide-
spread used.Table 3 Inhibitor resolution (years) in patients with
slowly resolving type inhibitors, dependent on inhibitor
type response
High responders Low responders Total
N° patients 15 32 47
Median (years) 6 3 5
Average (years) 12 7,8 8,7Limitations of the study
The value of this retrospective analysis has to be con-
sidered mainly exploratory, and some unaccounted
confounders might have played a role. Furthermore, as
studies on ITI do not have an internal control group of
patients not undergoing ITI, any inference from the
natural history of inhibitors to ITI treated patients and
vice-versa can only be considered as indirect. Some
characteristics of the population deserve mention. First,
the high rate of surgical synovectomy that occurred in
this study might have affected the rate of inhibitor ap-
pearance and disappearance. Second, the mean patient
age at inhibitor development was rather high, which is
explained by the fact that the study in question goes
back to the 70s and 80s, a period when concentrates
were still not widely available or extensively used.
Third, the intensity of treatment spun over a very high
range and was not used to adjust the analysis. How
these population characteristics could have affected theresults and impair their external validity remains to be
assessed.
The natural history of inhibitors: incidence
The cumulative inhibitor incidence in the cohort ap-
pears relatively high (34%), particularly so if compared
with reports from the same period, but it is in keeping
with similar studies conducted later on in other settings
[17-19] and substantially overlapping the results from
the recent prospective RODIN study [20].
The possibility of a higher incidence of inhibitors in
our cohort because of the surgery cannot be excluded
as it has been hypothesized that tissue damage would
trigger the immune system, raising the risk of develop-
ing inhibitors [21], but the same hypothesis has not
been confirmed in another case–control study [22].
Another possible explanation for this higher inci-
dence is that the inhibitor rate reported in previous
studies was incorrectly low. The low inhibitor rate in
the 1980s could actually be explained, as suggested by
Iorio et al. [18], by the combined effect of the year of
the studies (the older the study, the lower the rate, and
no study before the 1980s was included) and the test-
ing frequency. As discussed above, the cohort under-
went very frequent inhibitor testing, even when clinical
inefficacy was not suspected.
The natural history of inhibitors: clearance
In addition to 38% of transient inhibitors, 26% of
slowly resolving inhibitors disappeared in a median of
Table 4 Multinomial univariate logistic regression
Multinomial model Transient Slowly resolving Permanent
Inibitor titre § 1 3.63 62.0




Inibitor titre § 1 1.76 32.83
SE - 1.03 19.11
Inversions # 1 1.57 1.85
SE - 0.94 1.40
Nullmutations # 1 0.60 1.43




Model A – Inhibitor titre (180 cases).
Model B Inhibitor titre and gene mutation (131 cases).
§Regression coefficient for high titre versus low titre.
#Regression coefficient versus not null mutations.
We fitted two separate multinomial logistic regression models: one, in the
entire population, assessing the probability of developing a transient,
slowly resolving or permanent inhibitor associated with the initial inhibitor
titre (model A), and another, in those with the mutation available,
assessing the risk associated with both the initial inhibitor titre and the
gene mutation (model B), even if the model with the gene mutation alone
was not significant (probably due to insufficient sample size). We assumed
as baseline risk the patient with low titre inhibitor in model A and the
patient with low titre inhibitor and not null mutation in model B.
In model A, the relative risk ratio for a patient with a high responding over
one with low responding inhibitor to have a slowly resolving inhibitor is
3.63 (95% CI 1.39 – 9.47) and to have a permanent inhibitor is 62 (95% CI
21.12 – 182.00). The relative risk ratio for a permanent over a slow
resolving was 17.1 (95% CI 9.02 – 25.11). The predicted probabilities
estimated by the model and used to calculate the relative risk ratio are
reported in table.
In model B, after adding the gene mutation, the relative risk ratio for a
patient with a high responding over one with low responding inhibitor to
have a permanent inhibitor over a transient is 32.8 (95% CI 21.5 – 44.1) and
over a slowly resolving is 18.6 (95% CI 10.1 – 27.1), with no significant
effect associated to the gene mutation. The predicted probabilities
estimated by the model and used to calculate the relative risk ratio are
reported in table. The full parametric model with the interactions between
inhibitor titre and gene mutation (Log likelihood −102.122, LR chi2(10) =
76.87, Prob > chi2 = 0.0000, Pseudo R2 = 0.2734) showed that the effect of
the titre was not statistically significant when considered alone; on the
contrary, in patients with inversions compared to those with not null
mutations a statistically significant and clinically relevant increase in the
risk for permanent inhibitors in patients with high titre inhibitors (21.7,
95% CI 1.80 – 263) was found, together with a statistically significant but
not clinically relevant increase in patients with low titre inhibitors
(0.03,95% CI 0.001–0.73).
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The characteristics of the patients spontaneously clear-
ing their inhibitors are of interest, particularly when
contrasted with available evidence from ITI studies
[7,23-25]. First, the upper bound of ITI duration
needed to obtain tolerance is considered to be up to
33 months, close to the 3-year median time period for
spontaneous resolution of the inhibitors among thelow responders in our study cohort. Second, a low in-
hibitor titre has been recognized as significant predict-
ive factor for success of ITI, as it has shown to be in
our subgroup of slowly disappearing inhibitors, in
which 90% of low titre patients spontaneously lose the
inhibitor. Third, underlying haemophilia genotype has
been associated with the risk of anti-FVIII inhibitor de-
velopment [26-28] and the probability of ITI success
[29,30]; most patients with large deletions undergoing
ITI fail to respond whereas patients with int22inv have
an intermediate and variable success rate. The logistic
regression analysis performed in our study, though
limited by the small number of available patients and
incomplete accounting for all potential confounders,
seems to fit this picture.Conclusions
This long term observational study showed that the
prevalence of patients with truly persistent inhibitors
is 1/3, while 2/3 of inhibitors may resolve spontan-
eously These figures largely overlap with results
obtained in the ITI study cohorts [7,23-25]. The impli-
cations of these results may vary depending on the
clinical and societal setting (i.e. the range of treatments
available and affordable). If confirmed in controlled
clinical observations, more likely to happen in resource
poor settings where ITI is not yet standard of care,
these results pave the way to a risk stratification strat-
egy for the selection of treatment in patients with
inhibitors.
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